Background: Heart failure (HF) is a leading cause of morbidity and mortality globally, with Southeast Asia seeing a rising disease burden. Multidisciplinary HF clinics (MDHFCs) offer a structured approach to optimise guideline-directed medical therapy, yet their effectiveness in middle-income countries remains underreported. Methods: This retrospective observational study aims to evaluate clinical outcomes and treatment optimisation in patients with HF with reduced ejection fraction enrolled in a MDHFC in Sarawak, Malaysia. The study included 172 patients enrolled from 2016 to 2020 at Sarawak Heart Centre. Patients were followed for 12 months. Primary outcome was a composite of cardiovascular mortality, HF hospitalisation or ambulatory worsening HF visits. Secondary outcomes included changes in New York Heart Association class, echocardiographic parameters and prescriptions for HF therapies. Results: Over 12 months, no cardiovascular deaths were recorded. HF hospitalisation and ambulatory worsening HF occurred in 9.5% and 11.3% of patients, respectively. Significant improvements in left ventricular ejection fraction (24.5–39.1%, p<0.001) and New York Heart Association class were observed. Uptake of angiotensin receptor blockers, angiotensin receptor–neprilysin inhibitor, β-blockers, mineralocorticoid receptor antagonists and sodium–glucose cotransporter-2 inhibitors increased markedly, with β-blockers prescribed in 91.5% of patients. Triple therapy use rose from 49.4% to 59.1%; quadruple therapy uptake remained low (1.8%). Conclusion: The MDHFC model improved clinical outcomes, functional status and medication optimisation despite resource limitations. These findings support the feasibility and effectiveness of MDHFCs in similar healthcare settings and highlight their potential scalability in middle-income countries.
1 January 2022 in Revista da Sociedade Brasileira de Medicina Tropical
Background: Fractional flow reserve (FFR) using an invasive pressure wire is recommended to guide coronary revascularisation in stable coronary artery disease. Coronary angiography-based wire-free FFR (CAFFR) determines the significance of a coronary lesion without the requirement of a pressure wire. Deferral of revascularisation of coronary lesions with an FFR >0.8 has been shown to have similar outcomes to patients managed with optimal medical therapy. Objective: The aim of our study was to assess the performance and 12-month clinical outcomes in patients with CAFFR-guided percutaneous coronary intervention (PCI) deferral. Methods: This was a prospective study involving 69 patients (93 vessels) with angiographic stenosis of 30–90%. Patients with CAFFR ≤0.80 or poor image quality were excluded, leaving 29 patients (31 vessels) for analysis. All recruited patients had a CAFFR >0.80 and thus, PCI deferral. This cohort was followed up for 12 months. The primary endpoint was a composite of death from any cause, MI or target vessel revascularisation. Wired FFR was done for comparison on 14 patients (48%) at the operator’s discretion. Results: The mean age was 59.9 (±12.6) years. The majority of patients were men (83%; n=24), 41% (n=12) had diabetes, 62% (n=18) had hypertension, 59% (n=17) had dyslipidaemia, 62% (n=18) had a history of smoking. The mean left ventricular ejection fraction (LVEF) was 52 (±11.4)% and 76% of the patients had a recent acute coronary syndrome. We assessed the left anterior descending artery and 52% (n=16) of vessels had a mean CAFFR was 0.87. At 12 months, all patients were alive, 89.7% remained in chronic coronary syndrome (CCS) class 1 and 3.4% (n=1) of the study population met the primary outcome of target vessel revascularisation. Conclusion: CAFFR showed good agreement with wire-based FFR and 12-month outcomes showed that CAFFR-guided deferral of PCI was safe and comparable to wired-based FFR guidance.
17 March 2026 in Journal of Asian Pacific Society of Cardiology
Background: In Sarawak, Malaysia, non-cardiologist physician-led heart failure (HF) clinics were established to improve uptake of guideline-directed medical therapy (GDMT). The objective of this study was to describe GDMT implementation and clinical outcomes in patients with HF with reduced ejection fraction managed in physician-led clinics across Sarawak. Methods: A multicentre, retrospective cohort of adults (aged ≥18 years) with HF with reduced ejection fraction (left ventricular ejection fraction ≤40%) was followed in physician-led HF clinics at nine hospitals (1 January 2021 to 30 June 2023). Demographics, comorbidities, symptoms, left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide and GDMT use were collected at enrolment, 3 months (3M) and 6 months (6M). Outcomes were HF admission and all-cause mortality at 3M and 6M. Results: A total of 384 patients were enrolled (age 56.4 ± 13.7 years; 75.3% men). The comorbidity burden was high. Patients on three or more pillars of GDMT rose from 52% pre-clinic to 84% at 3–6M; use of four pillars increased from 12 to 49% at 6M. New York Heart Association class I increased from 26 to 60% by 6M. Among 150 patients with repeat echocardiography, left ventricular ejection fraction improved from 28.0 ± 7.6% to 39.7 ± 13.3%. N-terminal pro-B-type natriuretic peptide declined from 5,159 pg/ml (interquartile range 1,730–9,000) pre-clinic (n=19) to 611 (interquartile range 178–2,472) at 3M (n=30). By 3M, HF admission was 5.8% and mortality 4.2%; by 6M, HF admission was 7.7% and mortality was 10.4%. Conclusions: In a resource-constrained setting, a protocolised, physician-led clinic model achieved substantial GDMT uptake with improvements in symptoms alongside 3–6-month event rates comparable to other centres. These data support scaling pragmatic physician-led HF clinics to narrow evidence-to-practice gaps where specialist access is limited.
29 December 2023 in International Journal of Cardiology